293 related articles for article (PubMed ID: 37760542)
61. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC.
Sharma R; Pillai A; Marron TU; Fessas P; Saeed A; Jun T; Dharmapuri S; Szafron D; Naqash AR; Gampa A; Wang Y; Khan U; Muzaffar M; Lee CJ; Lee PC; Bulumulle A; Paul S; Bettinger D; Hildebrand H; Yehia M; Pressiani T; Kaseb A; Huang YH; Ang C; Kudo M; Nishida N; Personeni N; Rimassa L; Pinato DJ
Hepatol Commun; 2022 Jul; 6(7):1776-1785. PubMed ID: 35481940
[TBL] [Abstract][Full Text] [Related]
62. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
63. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
64. Case Report: Successful liver transplantation after achieving complete clinical remission of advanced HCC with Atezolizumab plus Bevacizumab combination therapy.
Chouik Y; Erard D; Demian H; Schulz T; Mazard T; Hartig-Lavie K; Antonini T; Mabrut JY; Mohkam K; Rode A; Merle P
Front Immunol; 2023; 14():1205997. PubMed ID: 37377975
[TBL] [Abstract][Full Text] [Related]
65. Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma.
Jiang J; Diaz DA; Nuguru SP; Mittra A; Manne A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612046
[TBL] [Abstract][Full Text] [Related]
66. Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review.
Jin X; Zhang K; Fang T; Zeng X; Yan X; Tang J; Liang Z; Xie L; Zhao D
Front Oncol; 2022; 12():951303. PubMed ID: 36119543
[TBL] [Abstract][Full Text] [Related]
67. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
68. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
69. Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Zeng P; Shen D; Zeng CH; Chang XF; Teng GJ
Curr Oncol Rep; 2020 Jun; 22(8):76. PubMed ID: 32596779
[TBL] [Abstract][Full Text] [Related]
70. Cancer Immunoprevention: Challenges and Potential Opportunities for Use of Immune Checkpoint Inhibitors.
Mohammed A; Shoemaker RH; Sei S
Cancer Prev Res (Phila); 2020 Nov; 13(11):897-900. PubMed ID: 32948608
[TBL] [Abstract][Full Text] [Related]
71. Use of Antibiotics during Immune Checkpoint Inhibitor Treatment Is Associated with Lower Survival in Hepatocellular Carcinoma.
Cheung KS; Lam LK; Seto WK; Leung WK
Liver Cancer; 2021 Nov; 10(6):606-614. PubMed ID: 34950183
[TBL] [Abstract][Full Text] [Related]
72. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
73. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
[TBL] [Abstract][Full Text] [Related]
74. Immune checkpoint inhibitors increase the risk of kidney transplant rejection: a real-world pharmacovigilance study.
Wu J; Huang J; Zhu J; He Z; Chen M; Gao S; Liang D; Yu X; Lu C
Expert Opin Drug Saf; 2023 Mar; 22(3):231-235. PubMed ID: 35929998
[TBL] [Abstract][Full Text] [Related]
75. Prognosis after liver transplantation in patients treated with anti-PD-1 immunotherapy for advanced hepatocellular carcinoma: case series.
Chen Z; Hong X; Wang T; Guo Y; Huang C; Li M; He X; Ju W; Chen M
Ann Palliat Med; 2021 Sep; 10(9):9354-9361. PubMed ID: 34412496
[TBL] [Abstract][Full Text] [Related]
76. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges.
Rizzo A; Ricci AD; Gadaleta-Caldarola G; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 Nov; 15(11):1245-1251. PubMed ID: 34431725
[TBL] [Abstract][Full Text] [Related]
77. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
Wang H; Yang H; Zhou X; Zhang X
Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
[TBL] [Abstract][Full Text] [Related]
78. Immunotherapy for Hepatocellular Carcinoma in the Setting of Liver Transplantation: A Review.
Lominadze Z; Hill K; Shaik MR; Canakis JP; Bourmaf M; Adams-Mardi C; Abutaleb A; Mishra L; Shetty K
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768686
[TBL] [Abstract][Full Text] [Related]
79. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
80. Toxicity Profiles of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.
Griffiths CD; Zhang B; Tywonek K; Meyers BM; Serrano PE
JAMA Netw Open; 2022 Jul; 5(7):e2222721. PubMed ID: 35849393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
